This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Chronic Obstructive Pulmonary Disease  • Pneumonia  • Quality of Care  • Evidence-Based Medicine  • Drug Therapy  • Adverse Effects  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Meta-analysis

Sonal Singh, MD, MPH; Aman V. Amin, MD; Yoon K. Loke, MD

Arch Intern Med. 2009;169(3):219-229.

Background  Recent studies have suggested a possible association between pneumonia and the use of inhaled corticosteroids. We aimed to ascertain the risk of pneumonia with long-term inhaled corticosteroid use among patients with chronic obstructive pulmonary disease (COPD).

Methods  We performed systematic searches with no date restrictions through June 30, 2008, of MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, regulatory documents, and trial registries. We included randomized controlled trials of any inhaled corticosteroid vs a control treatment for COPD, with at least 24 weeks of follow-up and reporting of pneumonia as an adverse event. Outcomes evaluated included any pneumonia, serious pneumonia, pneumonia-related mortality, and overall mortality.

Results  Eighteen randomized controlled trials (n = 16 996) with 24 to 156 weeks of follow-up were included after a detailed screening of 97 articles. Inhaled corticosteroids were associated with a significantly increased risk of any pneumonia (relative risk [RR], 1.60; 95% confidence interval [CI], 1.33-1.92 [P < .001]; I² = 16%) and serious pneumonia (1.71; 1.46-1.99 [P < .001]; I² = 0%) but without a significantly increased risk of pneumonia-related mortality (1.27; 0.80-2.03 [P = .31]; I² = 0%) or overall mortality (0.96; 0.86-1.08 [P = .51]; I² = 0%). Inhaled corticosteroids were associated with a significantly increased risk of serious pneumonia when compared with placebo (RR, 1.81; 95% CI, 1.44-2.29 [P < .001]) or when the combination of inhaled corticosteroids and long-acting β-agonists was compared with long-acting β-agonists (1.68; 1.20-2.34 [P = .002]).

Conclusion  Among patients with COPD, inhaled corticosteroid use for at least 24 weeks is associated with a significantly increased risk of serious pneumonia, without a significantly increased risk of death.

Author Affiliations: Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina (Drs Singh and Amin); Clinical Pharmacology, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, England (Dr Loke).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inhaled Corticosteroids vs Placebo for Preventing COPD Exacerbations: A Systematic Review and Metaregression of Randomized Controlled Trials
Agarwal et al.
Chest 2010;137:318-325.
ABSTRACT | FULL TEXT  

Predicting Corticosteroid Response in Chronic Obstructive Pulmonary Disease Using Exhaled Nitric Oxide
Dummer et al.
Am. J. Respir. Crit. Care Med. 2009;180:846-852.
ABSTRACT | FULL TEXT  

Safety and Efficacy of Combined Long-Acting {beta}-Agonists and Inhaled Corticosteroids vs Long-Acting {beta}-Agonists Monotherapy for Stable COPD: A Systematic Review
Rodrigo et al.
Chest 2009;136:1029-1038.
ABSTRACT | FULL TEXT  

All you need to read in the other general journals
BMJ 2009;338:b627-b627.
FULL TEXT  

Chronic Obstructive Pulmonary Disease
Braman
ACCP Pulmonary Med Brd Rev 2009;25:153-186.
FULL TEXT